In vitro B cell experiments explore the role of CD24, CD38, and energy metabolism in ME/CFS

Front Immunol. 2024 Jan 8:14:1178882. doi: 10.3389/fimmu.2023.1178882. eCollection 2023.

Abstract

Introduction: Disturbances of energy metabolism contribute to the clinical manifestations of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Previously, we found that B cells from ME/CFS patients have an increased expression of CD24, a modulator of many cellular functions including those of cell stress. The relative ability of B cells from ME/CFS patients and healthy controls (HC) to respond to rapid changes in energy demand was compared.

Methods: CD24, the ectonucleotidases CD39 and CD73, the NAD-degrading enzyme CD38, and mitochondrial mass (MM) were measured following cross-linking of the B cell receptor and costimulation with either T-cell-dependent or Toll-like-receptor-9-dependent agonists. The levels of metabolites consumed/produced were measured using 1H-NMR spectroscopy and analyzed in relation to cell growth and immunophenotype.

Results: Proliferating B cells from patients with ME/CFS showed a lower mitochondrial mass and a significantly increased usage of essential amino acids compared with those from HC, with a significantly delayed loss of CD24 and an increased expression of CD38 following stimulation.

Discussion: The immunophenotype results suggested the triggering of a stress response in ME/CFS B cells associated with the increased usage of additional substrates to maintain necessary ATP levels. Disturbances in energy metabolism in ME/CFS B cells were thus confirmed in a dynamic in vitro model, providing the basis for further mechanistic investigations.

Keywords: B cells; CD24; chronic fatigue syndrome; metabolism; metabolomics.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Immunologic
  • B-Lymphocytes
  • CD24 Antigen
  • Energy Metabolism
  • Fatigue Syndrome, Chronic*
  • Humans
  • Receptors, Antigen, B-Cell

Substances

  • Receptors, Antigen, B-Cell
  • Adjuvants, Immunologic
  • CD24 protein, human
  • CD24 Antigen

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was funded by Ramsey/Solve ME, Open Medicine Foundation, and the Invest in ME charity (registered UK charity number: 1114035).